Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5819959 | 0.75 | PRCP (0.43) | HTR2A | |
| SCHEMBL15940121 | 0.75 | TAAR1 (0.35) | PARP1 | |
| SCHEMBL27814188 | 0.72 | CYP1A2 (0.39) | BRD4CCL2HTR2AHDAC3 | |
| SCHEMBL28294761 | 0.71 | PARP1 (0.37) | PARP1HDAC3 | |
| SCHEMBL30399174 | 0.68 | HTR2C (0.42) | PARP1HTR2AHDAC3 | |
| SCHEMBL29531849 | 0.66 | ALDH1A1 (0.34) | BRD4CCL2 | |
| SCHEMBL27898029 | 0.66 | HTR2C (0.39) | PARP1HTR2AHTR6 | |
| SCHEMBL30364155 | 0.65 | MAPK1 (0.35) | PARP1HDAC3 | |
| SCHEMBL19691139 | 0.65 | MAPK1 (0.35) | PARP1HDAC3 | |
| SCHEMBL6298168 | 0.64 | HDAC3 (0.38) | PARP1BRD4CCL2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PDE5A, PDE3A, PDE3B | PARP1 1567/4885BRD4 495/4885CCL2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.